For type 2 diabetes mellitus. ANDA 91184, held by Alkem. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 91184 (Metformin Hydrochloride), held by Alkem, was first approved by FDA on Nov 1, 2010, with 4 approved supplements and 0 published complete response letters.
Metformin hydrochloride tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 1, 2010 | Original application | Approved | None posted |
| Metformin Hydrochloride500MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride850MG · tablet;oral | Metformin Hydrochloride | Rx |
| Metformin Hydrochloride1GM · tablet;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 17Labeling · Standard review | Approved | None posted |
| Feb 2, 2019 | Supplement 10Labeling · Standard review | Approved | None posted |
| Feb 2, 2019 | Supplement 12Labeling · Standard review | Approved | None posted |
| Oct 5, 2012 | Supplement 3Manufacturing | Approved | None posted |
| Nov 1, 2010 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters